Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Diabetes Care

Volumn 37, Issue 4, 2014, Pages 985-992

  Turner, Lydia W ^a   Nartey, David ^a   Stafford, Randall S ^b   Singh, Sonal ^a,c   Alexander, G Caleb ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS SITAGLIPTIN; NOVALOG MIX; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; SITAGLIPTIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

AMBULATORY CARE; ARTICLE; CROSS-SECTIONAL STUDY; DRUG COST; DRUG USE; HUMAN; MEDICAL AUDIT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; TREND STUDY; UNITED STATES; AGED; CLASSIFICATION; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MIDDLE AGED;

AGED; AMBULATORY CARE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; UNITED STATES;

EID: 84897868393     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2097     Document Type: Article

References (35)

1. Diabetes Statistics. Data from the 2011 National Diabetes Fact Sheet (released January 26, 2011). Available from http://www.diabetes.org/diabetes- basics/diabetes-statistics/. Accessed 22 August 2013
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
3. Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45:S13-S17 (Pubitemid 34762209)
4. Alexander GC, Tseng CW. Six strategies to identify and assist patients burdened by out-of-pocket prescription costs. Cleve Clin J Med 2004;71:433-437 (Pubitemid 38821202)
5. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 2004;164:1134-1139 (Pubitemid 38668994)
6. Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care 2010;33:823-825
7. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD005613
8. Ahŕen B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-876 (Pubitemid 40115912)
9. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
10. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286 (Pubitemid 351160260)
11. Boland CL, Degeeter M, Nuzum DS, Tzefos M. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 agonists. Ann Pharmacother 2013;47:490-505
12. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
13. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning - geographic variation in the use of rosiglitazone. N Engl J Med 2010; 363:2081-2084
14. Rodbard HW, Jellinger PS. Physicians' prescribing patterns for patients with diabetes are changing for the better. Am J Med 2012;125:e11-e12
15. U.S. Bureau of Labor Statistics. Consumer price index inflation calculator. http://www.bls.gov/data/in flation-calculator.htm. Accessed 9 October 2013
16. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
17. Bergenstal RM, Wysham C, Macconell L, et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-439
18. Russell-Jones D, Vaag A, Schmitz O, et al.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055
19. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258, e22
20. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
21. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
22. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocrine Practice 2009 Sept/Oct; 15(6): 540-559. Update notice. Endocr Pract 2009;15:768-770
23. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-549
24. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539
25. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-2031
26. FDA panel urges looser restrictions on diabetes drug Avandia [article online]. Available from: http://www.cnn.com/2013/06/06/health/fda- avandiarestrictions/index.html. Accessed 9 October 2013
27. Bodmer M, Meier C, Kr̈ahenb̈uhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-2091
28. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-189
29. Bolen S, Wilson L, Vassy J, et al. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Comparative Effectiveness Review No. 8. (Prepared by Johns Hopkins Evidence-based Practice Center under contract No. 290-02-0018.) Rockville, MD: Agency for Healthcare Research and Quality, July 2007. Available from www.effectivehealthcare.ahrq. gov/reports/final.cfm. Accessed 29 October 2013
30. Robinson JD, Neumiller JJ, Campbell RK. Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec. Drugs 2012;72:2319-2325
31. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34(Suppl. 2):S276-S278
32. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009;76 (Suppl. 5):S28-S38
33. Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010;33:695-700
34. Catalano R. Health, medical care, and economic crisis. N Engl J Med 2009;360:749-751
35. Ratner RE. Diabetesmanagement in the age of national health reform. Diabetes Care 2011;34:1054-1057